Table 2.

Results of univariate analysis of disease-free survival and overall survival after cholangiocarcinoma radical surgery.

Variable	Grouping	Disease-free survival		Overall survival
		Median OS (month)	P value	Median OS (month)	P value
WBC (10^9/L)	<10	23.8	0.99	32.0	0.85
	≥10	25.8		36.1
Hb (g/L)	<120	30.3	0.93	35.2	0.92
	≥120	23.9		32.0
ALB (g/L)	<35	14.3	0.17	27.8	0.29
	≥35	24.6		32.3
AFP (ug/L)	<10	24.0	0.46	35.0	0.91
	≥10	16.2		25.1
CEA (ug/L)	<5	24.0	0.62	35.2	0.35
	≥5	19.9		27.8
CA19-9 (U/ml)	<35	41.1	0.04	53.7	0.01
	≥35	22.0		28.6
Tumor number	Single	23.9	0.95	32	0.67
	Multiple	38.5		47.8
Tumor size(cm)	<5	25.8	0.13	32.3	0.92
	≥5	15.6		32.0
Vascular invasion	No	27.3	0.00	36.1	0.00
	Yes	8.6		16.2
Pathological type	Intrahepatic	15.1	0.13	25.1	0.15
	Perihilar	23.8		32.0
	Distal	31.8		42.0
Differentiation degree	Poor	16.2	0.01	24.0	0.01
	Moderate	27.3		35.2
	Well	41.8		65.4
TNM stage	I	47.3	0.03	54.0	0.01
	II	20.1		28.6
	III	17.6		27.8
Adjuvant chemotherapy	Single drug	11.0	0.01	27.1	0.20
	Doublet drugs	24.6		31.3
Recurrence patterns	Local			31.2	0.01
	Regional			32.0
	Distant			20.4

WBC, white blood cell; Hb, hemoglobin; ALB, albumin; AFP, alpha fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; Single drug, mainly 5-fluorouracil (S-1 or capecitabine) adjuvant chemotherapy was administrated as follow:S-1 50 mg/m² or capecitabine 1250 mg/m² administered orally twice daily on days 1–14 for a 3-week cycle; Doublet drugs, mainly gemcitabine + capecitabine or S-1 adjuvant chemotherapy was administrated as follow: gemcitabine 1000 mg/m² administered intravenously on day 1 and S-1 50 mg/m² or capecitabine 1000 mg/m² administered orally twice daily on days 1–14 for a 3-week cycle.